Information Provided By:
Fly News Breaks for November 30, 2018
AGIO
Nov 30, 2018 | 07:50 EDT
Canaccord analyst John Newman noted Agios Pharmaceuticals already has an FDA black box warning for differentiation syndrome for both Tibsovo and Idhifa, so he is not concerned about the recent FDA warning notice regarding the condition. He does not believe it will result in any decrease in usage, but since both are relatively new drugs, it will take time for doctors and patients to become acquainted with their safety profile. Newman reiterated his Buy rating and $90 price target on Agios Pharmaceuticals shares.
News For AGIO From the Last 2 Days
There are no results for your query AGIO